The global erectile dysfunction market revenue was around US$ 2.3 billion in 2022 and is estimated to reach US$ 4.7 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.5% during the forecast period from 2023 to 2031.
Erectile dysfunction (ED) is defined as the inability to generate or maintain a robust sufficient penile erection during sexual engagement. It is the most common problem impacting male sexual health. Stress affects the patient's mental and physical health. Erectile dysfunction has two primary causes: psychological and physiological. High cholesterol, high blood pressure, diabetes, obesity, tobacco, and smoking usage are all physiological factors.
Market Driving Factors
Obesity, diabetes, and cardiovascular disease are on the rise as people embrace an unhealthy lifestyle, which leads to concerns like ED as they age. Young people's present lifestyles are extremely stressful in many developing countries, which has leading to a rise in fast food and ready-to-eat food consumption, as well as smoking and drinking. These factors are compromising overall fitness and health, which in turn increases the risk of ED. Additionally, the number of ED patients grows along with the senior population growth, which continues to be a main driver of the market expansion.
Major and emerging pharmaceutical brands have increased their investments in developing countries such as China, India, Africa, and key Middle Eastern countries over the last few years. This had a significant impact on the price of medicine and the distribution and availability of medicines within the nations, both of which are predicted to be crucial. The erectile dysfunction medications are also anticipated to grow dramatically due to the increased advertising investments and these elements propel the market growth.
The severe adverse effects associated with erectile dysfunction drugs limit the use of medicines and have a negative impact on market growth. For instance, common erectile dysfunction drug side effects include face flushing, headache, and back pain. However, serious adverse effects include eyesight and hearing loss.
Regional Analysis
North America dominated the market in terms of revenue. This can be attributed to the high illness burden, excellent healthcare infrastructure, and approval of innovative products for treatment. For instance, lupin received FDA permission for its ANDA (Abbreviated New Drug Application) for sildenafil (10 mg/mL oral suspension) to market a generic equivalent to Revatio of Viatris Specialty LLC. The availability of low-cost generic products may rise patient compliance, hence expanding the consumer base and income for the market in the region.
Asia Pacific is estimated to dominate the market during the projection period. The growth of the region is due to the introduction of new products. For instance, IX Biopharma stated that the supply of Silcap and Wafesil through telemedicine in Australia for the treatment of an adult patient with erectile dysfunction.
Segmentation Insights
In terms of product insights, the Viagra segment dominated the market in terms of revenue. Many firms are currently pursuing numerous strategic initiatives such as partnerships, research collaborations, and agreements to increase their business footprint. For instance, Digital Men's Clinic Roman and Pfizer Inc signed a supply agreement to offer a generic version of Viagra to Roman members. This supply deal is likely to support the segment's growth.
Prominent Companies
Segmentation Outline
The global erectile dysfunction market segmentation focuses on Product and Region.
By Product
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL ERECTILE DYSFUNCTION MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: ERECTILE DYSFUNCTION MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL ERECTILE DYSFUNCTION MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL ERECTILE DYSFUNCTION MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 VIAGRA
5.3 CIALIS
5.4 ZYDENA
5.5 LEVITRA
5.6 STENDRA
5.7 OTHERS
6 GLOBAL ERECTILE DYSFUNCTION MARKET, BY GEOGRAPHY
6.1 OVERVIEW
6.2 NORTH AMERICA
6.2.1 NORTH AMERICA MARKET SNAPSHOT
6.2.2 U.S.
6.2.3 CANADA
6.2.4 MEXICO
6.3 EUROPE
6.3.1 EUROPE MARKET SNAPSHOT
6.3.2 WESTERN EUROPE
6.3.2.1 THE UK
6.3.2.2 GERMANY
6.3.2.3 FRANCE
6.3.2.4 ITALY
6.3.2.5 SPAIN
6.3.2.6 REST OF WESTERN EUROPE
6.3.3 EASTERN EUROPE
6.3.3.1 POLAND
6.3.3.2 RUSSIA
6.3.3.3 REST OF EASTERN EUROPE
6.4 ASIA PACIFIC
6.4.1 ASIA PACIFIC MARKET SNAPSHOT
6.4.2 CHINA
6.4.3 JAPAN
6.4.4 INDIA
6.4.5 AUSTRALIA & NEW ZEALAND
6.4.6 ASEAN
6.4.7 REST OF ASIA PACIFIC
6.5 MIDDLE EAST & AFRICA
6.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
6.5.2 UAE
6.5.3 SAUDI ARABIA
6.5.4 SOUTH AFRICA
6.5.5 REST OF MEA
6.6 SOUTH AMERICA
6.6.1 SOUTH AMERICA MARKET SNAPSHOT
6.6.2 BRAZIL
6.6.3 ARGENTINA
6.6.4 REST OF SOUTH AMERICA
7 GLOBAL ERECTILE DYSFUNCTION MARKET COMPETITIVE LANDSCAPE
7.1 OVERVIEW
7.2 COMPANY MARKET RANKING
7.3 KEY DEVELOPMENT STRATEGIES
7.4 COMPETITIVE DASHBOARD
7.5 PRODUCT MAPPING
7.6 TOP PLAYER POSITIONING, 2022
7.7 COMPETITIVE HEATMAP
7.8 TOP WINNING STRATEGIES
8 COMPANY PROFILES
8.1 PFIZER INC
8.1.1 OVERVIEW
8.1.2 FINANCIAL PERFORMANCE
8.1.3 PRODUCT OUTLOOK
8.1.4 KEY DEVELOPMENTS
8.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.2 ELI LILLY AND COMPANY
8.2.1 OVERVIEW
8.2.2 FINANCIAL PERFORMANCE
8.2.3 PRODUCT OUTLOOK
8.2.4 KEY DEVELOPMENTS
8.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.3 BAYER AG
8.3.1 OVERVIEW
8.3.2 FINANCIAL PERFORMANCE
8.3.3 PRODUCT OUTLOOK
8.3.4 KEY DEVELOPMENTS
8.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.4 VIVUS INC
8.4.1 OVERVIEW
8.4.2 FINANCIAL PERFORMANCE
8.4.3 PRODUCT OUTLOOK
8.4.4 KEY DEVELOPMENTS
8.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.5 DONG-A ST CO. LTD
8.5.1 OVERVIEW
8.5.2 FINANCIAL PERFORMANCE
8.5.3 PRODUCT OUTLOOK
8.5.4 KEY DEVELOPMENTS
8.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.6 MEDA PHARMACEUTICALS INC
8.6.1 OVERVIEW
8.6.2 FINANCIAL PERFORMANCE
8.6.3 PRODUCT OUTLOOK
8.6.4 KEY DEVELOPMENTS
8.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.7 S.K. CHEMICALS CO. LTD
8.7.1 OVERVIEW
8.7.2 FINANCIAL PERFORMANCE
8.7.3 PRODUCT OUTLOOK
8.7.4 KEY DEVELOPMENTS
8.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
8.8.1 OVERVIEW
8.8.2 FINANCIAL PERFORMANCE
8.8.3 PRODUCT OUTLOOK
8.8.4 KEY DEVELOPMENTS
8.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.9 ENDO INTERNATIONAL PLC
8.9.1 OVERVIEW
8.9.2 FINANCIAL PERFORMANCE
8.9.3 PRODUCT OUTLOOK
8.9.4 KEY DEVELOPMENTS
8.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.10 FUTURA MEDICAL PLC
8.10.1 OVERVIEW
8.10.2 FINANCIAL PERFORMANCE
8.10.3 PRODUCT OUTLOOK
8.10.4 KEY DEVELOPMENTS
8.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.11 APRICUS BIOSCIENCES INC
8.11.1 OVERVIEW
8.11.2 FINANCIAL PERFORMANCE
8.11.3 PRODUCT OUTLOOK
8.11.4 KEY DEVELOPMENTS
8.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.12 MEDTRONIC PLC
8.12.1 OVERVIEW
8.12.2 FINANCIAL PERFORMANCE
8.12.3 PRODUCT OUTLOOK
8.12.4 KEY DEVELOPMENTS
8.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.13 COLOPLAST CORP
8.13.1 OVERVIEW
8.13.2 FINANCIAL PERFORMANCE
8.13.3 PRODUCT OUTLOOK
8.13.4 KEY DEVELOPMENTS
8.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.14 BOSTON SCIENTIFIC CORPORATION
8.14.1 OVERVIEW
8.14.2 FINANCIAL PERFORMANCE
8.14.3 PRODUCT OUTLOOK
8.14.4 KEY DEVELOPMENTS
8.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.15 ZEPHYR SURGICAL IMPLANTS
8.15.1 OVERVIEW
8.15.2 FINANCIAL PERFORMANCE
8.15.3 PRODUCT OUTLOOK
8.15.4 KEY DEVELOPMENTS
8.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.16 UROLOGIX
8.16.1 OVERVIEW
8.16.2 FINANCIAL PERFORMANCE
8.16.3 PRODUCT OUTLOOK
8.16.4 KEY DEVELOPMENTS
8.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.17 AMERICAN MEDICAL SYSTEMS
8.17.1 OVERVIEW
8.17.2 FINANCIAL PERFORMANCE
8.17.3 PRODUCT OUTLOOK
8.17.4 KEY DEVELOPMENTS
8.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.18 AUGUSTA MEDICAL SYSTEMS
8.18.1 OVERVIEW
8.18.2 FINANCIAL PERFORMANCE
8.18.3 PRODUCT OUTLOOK
8.18.4 KEY DEVELOPMENTS
8.18.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
8.19 POS-T-VAC MEDICAL
8.19.1 OVERVIEW
8.19.2 FINANCIAL PERFORMANCE
8.19.3 PRODUCT OUTLOOK
8.19.4 KEY DEVELOPMENTS
8.19.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
著作権 ©2022 無断複写・転載を禁じます
